Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

Influenza virus

Influenza A virus hemagglutinin (HA)

In vitro and mouse studies suggest the HA-targeting mAb CO5 could help prevent or treat influenza infection. In vitro, CO5 neutralized influenza virus subtypes H1, H2, H3 and H9 by binding the HA globular head domain rather than the stem region targeted by most broadly neutralizing antibodies. In mouse models of H1N1 and H3N2 influenza virus infection, CO5 given 24 hours before lethal challenge resulted in 100% survival. In the same models, CO5 given up to 3 days after infection also resulted in 100% survival. Ongoing work includes developing stable cell line production of the antibody.

SciBX 5(38); doi:10.1038/scibx.2012.1009
Published online Sept. 27, 2012

Covered by issued and pending patents; available for licensing

Ekiert, D.C. et al. Nature; published online Sept. 16, 2012;
doi:10.1038/nature11414
Contact: Ian A. Wilson, The Scripps Research Institute, La Jolla, Calif.
e-mail:
wilson@scripps.edu

Contact: Ramesh R. Bhatt, Sea Lane Biotechnologies LLC, Mountain View, Calif.
e-mail:
ramesh.bhatt@sealanebio.com